Clinical trial · Observational
A Prospective Cohort of Pulmonary Ground Glass Nodules Patients With Family History.
Clinical Database and Biobank of Pulmonary Ground Glass Nodules Patients With Family History, a Prospective Cohort Study.
NCT04220268CI-TRIAL-00042611GGN-FunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the present prospective cohort study (GGN-F) is to study the family aggregation of pulmonary ground glass nodules via the questionnaire survey and to investigate the underlying genetic mechanism via the biobank.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Family Research | — | UNRESOLVED | — |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Participants
- description
- All the patients with proved malignant ground glass nodule will be enrolled.
Primary outcomes (1)
- measure
- The prevalence of family aggregation of pulmonary ground glass nodule.
- timeFrame
- 1 week
- description
- To investigate the aggregation of pulmonary ground glass nodule among first-degree relatives of participants via the questionnaire.
Secondary outcomes (1)
- measure
- Susceptibility genetic events related to the family aggregation of ground glass nodules.
- timeFrame
- 1 month
- description
- To investigate the underlying susceptibility genetic loci which concern with familial inheritance of ground glass nodule.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. patients with informed consent; 2. patients with pulmonary ground glass nodule. 3. pathological proved early stage lung cancer. Exclusion Criteria: 1.not included in the inclusion criteria
References
Publications (1)
- BACKGROUNDDai J, Lv J, Zhu M, Wang Y, Qin N, Ma H, He YQ, Zhang R, Tan W, Fan J, Wang T, Zheng H, Sun Q, Wang L, Huang M, Ge Z, Yu C, Guo Y, Wang TM, Wang J, Xu L, Wu W, Chen L, Bian Z, Walters R, Millwood IY, Li XZ, Wang X, Hung RJ, Christiani DC, Chen H, Wang M, Wang C, Jiang Y, Chen K, Chen Z, Jin G, Wu T, Lin D, Hu Z, Amos CI, Wu C, Wei Q, Jia WH, Li L, Shen H. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17. PMID 31326317